Business
Holdings in Company
M&G Plc has increased its holding in Ondine Biomedical Inc. to 14.29% of the voting rights, crossing a 1% threshold. This change, effective March 16, 2026, represents a total of 74,268,775 voting rights. The previous notification showed a holding of 13.04%. The notification was made on March 17, 2026, and the increase is due to movements within M&G Plc's controlled undertakings. Disclaimer*
About this update from Ondine Biomedical, Inc.
TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN CA68234M2058 Issuer Name ONDINE BIOMEDICAL INC UK or Non-UK Issuer Non-UK 2. Reason for Notification Other Comments Movement of 1% as per Articles 3. Details of person subject to the notification obligation Name M&G Plc City of registered office (if applicable) London Country of registered office (if applicable) United Kingdom 4. Details of the shareholder Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above City of registered office (if applicable) Country of registered office (if applicable) 5. Date on which the threshold was crossed or reached 16-Mar-2026 6. Date on which Issuer notified 17-Mar-2026 7. Total positions of person(s) subject to the notification obligation % of voting rights attached to shares (total of 8.A) % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) Total number of voting rights held in issuer Resulting situation on the date on which threshold was crossed or reached 14.294787 0.000000 14.294787 74268775 Position of previous notification (if applicable) 13.041900 0.000000 13.041900 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached 8A. Voting rights attached to shares Class/Type of shares ISIN code(if possible) Number of direct voting rights (DTR5.1) Number of indirect voting rights (DTR5.2.1) % of direct voting rights (DTR5.1) % of indirect voting rights (DTR5.2.1) CA68234M2058 74268775 14.294787 Sub Total 8.A 74268775 14.294787% 8B1. Financial Instruments according to (DTR5.3.1R.(1) (a)) Type of financial instrument Expiration date Exercise/conversion period Number of voting rights that may be acquired if the instrument is exercised/converted % of voting rights Sub Total 8.B1 8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b)) Type of financial instrument Expiration date Exercise/conversion period Physical or cash settlement Number of voting rights % of voting rights Sub Total 8.B2 9. Information in relation to the person subject to the notification obligation 2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary) Ultimate controlling person Name of controlled undertaking % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold M&G Plc M&G Plc (Parent company) 14.294787% 14.294787% M&G Plc M&G Group Regulated Entity Holding Company Limited (wholly owned subsidiary of M&G Plc) 14.294787% 14.294787% M&G Plc M&G Group Limited (wholly owned subsidiary of M&G Group Regulated Entity Holding Company Limited) 14.294787% 14.294787% M&G Plc M&G FA Limited (wholly owned subsidiary of M&G Group Limited) 14.294787% 14.294787% M&G Plc M&G Investment Management Limited (wholly owned subsidiary of M&G FA Limited) 14.294787% 14.294787% 10. In case of proxy voting Name of the proxy holder The number and % of voting rights held The date until which the voting rights will be held 11. Additional Information 12. Date of Completion 17-Mar-2026 13. Place Of Completion London, United Kingdom
View stock analysis, news, and events for Ondine Biomedical, Inc.